Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Intra-Cellular Therapies

Status and phase: Completed; Phase 3

Conditions: Major Depressive Disorder; Bipolar Depression

Treatments: Drug: Lumateperone; Drug: Placebos

Study type: Interventional

Funder types: Industry

Identifiers

NCT04285515

ITI-007-403

Details and patient eligibility

About

This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or Bipolar II Disorder (Bipolar Depression) or major depressive disorder (MDD) who also meet the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM-5) criteria for mixed-features. The study consists of a Screening Period, a Double-blind Treatment Period, and a Safety Follow-up Period.

Enrollment: 488 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Major Inclusion Criteria:

• Male or female subjects of any race, ages 18-75 inclusive
• Meets the Diagnostic and Statistical Manual of Mental Disorder, 5th Edition (DSM 5) criteria for Bipolar I or Bipolar II Disorder or MDD
• The start of the current major depressive episode is at least 2 weeks but no more than 6 months prior to the Screening (Visit 1)
• Has at least moderate severity of illness, as measured by a rater-administered MADRS total score ≥ 24 and corresponding to a CGI S score of ≥ 4 at Screening (Visit 1) and Baseline (Visit 2)
• The patient meets the DSM-5 criteria for mixed-features specific to the Bipolar I or II diagnosis or MDD diagnosis
• Current major depressive episode is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning
• Able to provide written informed consent

Major Exclusion Criteria:

• Any female subject who is pregnant or breast-feeding
• Any subject judged to be medically inappropriate for study participation
• The patient has a significant risk for suicidal behavior
• The patient presents with a lifetime history of epilepsy, seizure or convulsion, or electroencephalogram with clinically significant abnormalities, delirium, dementia, amnestic, or other cognitive disorder or significant brain trauma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

488 participants in 2 patient groups, including a placebo group

Lumateperone 42mg

Experimental group

Description:

Lumateperone 42mg administered once daily in the evening

Treatment:

Drug: Lumateperone

Placebo

Placebo Comparator group

Description:

Matching placebo administered once daily in the evening

Treatment:

Drug: Placebos